MOTS-c vs AOD-9604: Metabolic Peptides Compared

MOTS-c and AOD-9604 are metabolic peptides but work via different mechanisms. MOTS-c is a mitochondrial-derived peptide (microprotein) that improves insulin sensitivity and mitochondrial function. AOD-9604 is a fragment of human growth hormone that stimulates lipolysis and metabolic rate without GH effects. Both claim metabolic benefits but address different problems.

Mechanism: Mitochondrial-derived microprotein; activates AMPK and improves mitochondrial oxidative capacity. Signals via OXSR1 (oxidative stress-responsive kinase).

Mechanism of action: Improves mitochondrial efficiency, enhances glucose utilization, reduces insulin resistance.

Animal evidence: Strong; improves insulin sensitivity, increases exercise capacity, and extends lifespan in mice. Prevents metabolic syndrome in diet-induced obesity models.

Human evidence: Minimal; one small study showed improved exercise capacity. No human metabolic or weight loss studies published.

Fat loss efficacy: Primarily through improved metabolism (indirect), not direct lipolysis. No direct evidence of fat loss in humans.

Side effects: Minimal reported; generally well-tolerated in animal studies.

Route: Injectable peptide.

Cost: $150-300/month.

Status: Research compound; very limited human data.

Mechanism: C-terminal fragment of human growth hormone (amino acids 177-191); stimulates lipolysis and increases metabolic rate without GH/IGF-1 effects.

Mechanism of action: Directly activates lipolysis (fat breakdown) via β-adrenergic receptors; increases metabolic rate; possible modest appetite suppression.

Animal evidence: Moderate; demonstrates fat loss and weight reduction in obese animals without causing hyperglycemia.

Human evidence: Very limited; small pilot studies suggest modest fat loss (2-5 kg over 8-12 weeks). No large randomized trials published.

Fat loss efficacy: Modest; approximately 2-5 kg over 12 weeks in pilot studies (weak evidence).

Side effects: Minimal; generally well-tolerated. Possible mild hyperactivity (due to increased metabolic rate).

Route: Injectable peptide.

Cost: $100-250/month.

Status: Research compound; limited human evidence.

Choose MOTS-c if: - You prioritize mitochondrial health (strongest mechanistic basis) - You want improved insulin sensitivity (better evidence pathway) - You're interested in exercise capacity enhancement (modest animal evidence)

Choose AOD-9604 if: - You want direct fat loss (most specific mechanism for weight loss) - You prioritize lipolysis stimulation (more direct than MOTS-c) - You're willing to accept weak human evidence

Bottom line: Both are research compounds with minimal human evidence. MOTS-c has stronger animal data for metabolic improvement but zero human weight loss evidence. AOD-9604 has modest pilot weight loss evidence but effect sizes are small. Neither should be considered proven for weight loss; GLP-1s (semaglutide, tirzepatide) have far superior evidence. If using either, realistic expectations are essential.